Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Moderate-to-severe Acute Pain Clear all

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: VNX001; Drug
Lead sponsor: Vaneltix Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Tucson, Arizona • Fresno, California • Tustin, California + 2 more

Conditions: Moderate to Severe Postoperative Pain
Interventions: Q8003, Morphine sulfate, Oxycodone HCl; Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 2 more

Conditions: Acute Pain
Interventions: XARTEMIS XR; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Durham, North Carolina • Pittsburgh, Pennsylvania

Conditions: Acute Moderate to Severe Pain
Interventions: Q8003, Placebo; Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Anaheim, California • Pasadena, Maryland • Altoona, Pennsylvania + 2 more

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108 5 mg, Norco, Placebo; Drug
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more

Conditions: Moderate to Severe Acute Postoperative Pain
Interventions: Tapentadol; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 1 Day to 23 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Palo Alto, California • Louisville, Kentucky • Durham, North Carolina + 1 more

Conditions: Acute Pain
Interventions: TRV130, Morphine, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 1 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: VNX001, Placebo, Lidocaine, Heparin; Drug
Lead sponsor: Vaneltix Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Escondido, California • Los Angeles, California • Newport Beach, California + 10 more

Conditions: Acute Pain, Postoperative
Interventions: IV acetaminophen, Oral acetaminophen, Morphine; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Pensacola, Florida • Columbus, Ohio

Conditions: Pain, Acute
Interventions: Fentanyl, Fentanyl and Ketamine, Ketamine; Drug · Combination Product
Lead sponsor: Mercy Health Ohio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Postoperative Pain
Interventions: Q8003 (morphine sulfate and oxycodone hydrochloride), Morphine sulfate, Oxycodone HCl; Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 4
States / cities: Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 1 more

Conditions: Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
Interventions: telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment; Behavioral · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 35 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pain
Interventions: Hydromorphone; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years to 64 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Pain
Interventions: Cebranopadol 400 ug; Drug
Lead sponsor: Adneuris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Riverside, California • Longmont, Colorado + 11 more

Conditions: Acute Pain
Interventions: Cebranopadol, Oxycodone IR, Placebo Only, Placebo; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Sheffield, Alabama • Little Rock, Arkansas • Tampa, Florida + 7 more

Conditions: Cyclic Vomiting Syndrome
Interventions: 3mg AZ-010, 1mg AZ010, Staccato Placebo; Combination Product
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Lancaster, California • Los Angeles, California • San Diego, California + 14 more

Conditions: Pain
Interventions: TRV130; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Pain
Interventions: Oliceridine, Placebo, Morphine; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 2 more

Conditions: Acute Post-surgical Pain
Interventions: Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo; Drug
Lead sponsor: Esteve Pharmaceuticals, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more

Search by objective public record fields.

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain

A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV

Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old

A Study of TRV130 for the Treatment of Pain After Bunionectomy

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain

Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain

Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients

Quality of Life in Younger Leukemia and Lymphoma Survivors

Safety Study of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg for Adult ED Patients

An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

A Pilot Study of TRV130 for the Treatment of Fracture Pain

Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.